Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 16/20 | 0.60 |
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | CASP6 | P55212 | 2/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802628 | 0.90 | CASP1 (0.74) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL3686640 | 0.90 | CASP1 (0.74) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL6281724 | 0.88 | CASP1 (0.59) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL6801541 | 0.88 | CASP1 (0.59) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL3323729 | 0.88 | CASP1 (0.59) | CASP1CASP3 | |
| SCHEMBL645918 | 0.86 | CASP3 (0.57) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL7893591 | 0.85 | CASP1 (0.66) | CASP1CASP3 | |
| SCHEMBL6802721 | 0.79 | CASP3 (0.55) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL8247253 | 0.77 | CASP3 (0.67) | CASP1CASP3CASP6CASP8 | |
| SCHEMBL7745119 | 0.77 | CASP3 (0.67) | CASP1CASP3CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3525791-B1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RES & DEV FOUNDATION (IL) | 2025-05-21 | — | — | EP | claimed |
| US-20200046796-A1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2020-02-13 | — | — | US | claimed |
| EP-3525791-A1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | Technion Research & Development Foundation Limited (IL) | 2019-08-21 | — | — | EP | claimed |
| WO-2018069885-A1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2018-04-19 | — | — | WO | claimed |
| US-6180402-B1 | REDUCING SIDE EFFECTS OR ENHANCING SELECTIVITY OF THERAPY BY CONTACTING LIVING CELLS WITH PHOTOSENSITIZING AGENT AND AT LEAST ONE CYSTEINE OR SERINE PROTEASE INHIBITOR | QLT INC. (CA) | 2001-01-30 | — | — | US | claimed |
| WO-1998022098-A2 | CPP32 INHIBITORS FOR REGULATING APOPTOSIS | QLT PHOTOTHERAPEUTICS, INC. (CA) | 1998-05-28 | — | — | WO | claimed |
| EP-3525791-B1 | USE OF CASPASE-3 INHIBITORS AND CASPASE-3 ACTIVATORS IN THE MANUFACTURE OF MEDICAMENT FOR TREATING CANCER AND WOUND HEALING | TECHNION RES & DEV FOUNDATION (IL) | 2025-05-21 | — | — | EP | disclosed |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240287574-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2024-08-29 | — | — | US | disclosed |
| US-20030224399-A1 | Methods for determining the prognosis for patients with a prostate neoplastic condition | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2003-12-04 | — | — | US | disclosed |
| US-20030165887-A1 | Methods for determining the prognosis for cancer patients using tucan | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-09-04 | — | — | US | disclosed |
| WO-2003061519-A2 | METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2002090931-A2 | METHODS FOR DETERMINING THE PROGNOSIS FOR CANCER PATIENTS USING TUCAN | THE BURNHAM INSTITUTE (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002064619-A2 | PEPTIDES THAT INHIBIT POLY-GLUTAMINE AGGREGATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-08-22 | — | — | WO | disclosed |
| US-6180402-B1 | REDUCING SIDE EFFECTS OR ENHANCING SELECTIVITY OF THERAPY BY CONTACTING LIVING CELLS WITH PHOTOSENSITIZING AGENT AND AT LEAST ONE CYSTEINE OR SERINE PROTEASE INHIBITOR | QLT INC. (CA) | 2001-01-30 | — | — | US | disclosed |
| WO-1998022098-A2 | CPP32 INHIBITORS FOR REGULATING APOPTOSIS | QLT PHOTOTHERAPEUTICS, INC. (CA) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CASP1 1854/4885CASP3 1797/4885CASP6 694/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | CASP1 1854/4885CASP3 1797/4885CASP6 694/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | CASP1 1854/4885CASP3 1797/4885CASP6 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.